Heart attacks often strike without warning. Doctors look for signs of plaque buildup in arteries, but not all plaques are the same. Some are stable, while others are prone to rupture and cause a blockage. This review explores a new way to look at the immune cells inside these plaques. Specifically, it focuses on macrophages, which are white blood cells that clean up debris but can also drive inflammation. The study looks at how different states of these cells might signal higher or lower risk. Understanding these states could help doctors see who is at greatest danger before a crisis happens. The research points to potential uses in risk stratification, molecular imaging, and targeting specific therapies. However, the findings come with important caveats. The data relied on plaque samples from different sources, which varied in how they were collected and labeled. Differences in how researchers named these cell states also made it hard to compare results directly. Because of these differences, the evidence is currently incomplete. While the potential for better risk prediction is clear, more work is needed to standardize how we measure these cells. Until then, this knowledge remains a promising but unfinished tool for heart care.
Review discusses translational potential of macrophage-state signatures for atherosclerosis risk stratification and therapeutic targetingMacrophage states in plaque may help predict heart attack risk
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This publication is a narrative review focusing on the translational potential of macrophage-state signatures within the context of atherosclerosis. The scope of the article centers on how these molecular signatures might inform risk stratification, molecular imaging techniques, and future therapeutic targeting strategies. No specific study population, sample size, or intervention details are provided in the source text.
The authors identify several key limitations that currently constrain the immediate clinical utility of these findings. These limitations include heterogeneity in plaque procurement methods, challenges with anatomic annotation, issues with computational integration, and inconsistencies in state nomenclature. These factors suggest that the current data cannot yet support definitive clinical recommendations.
The practice relevance is described as having translational potential rather than established efficacy. Because the source is a review and not a primary trial, no specific adverse events, safety data, or numerical outcomes are reported. Clinicians should interpret these findings as a hypothesis for future research rather than current evidence for patient management.